TYRA (Tyra Biosciences) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tyra Biosciences's Free Cash Flow for the three months ended in Dec. 2024 was $-19.60 Mil. Tyra Biosciences's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Tyra Biosciences's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Tyra Biosciences's current FCF Yield % is -13.58%.

The historical rank and industry rank for Tyra Biosciences's FCF Margin % or its related term are showing as below:

TYRA's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.165
* Ranked among companies with meaningful FCF Margin % only.

Tyra Biosciences FCF Margin % Historical Data

The historical data trend for Tyra Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences FCF Margin % Chart

Tyra Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

Tyra Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Tyra Biosciences's FCF Margin %

For the Biotechnology subindustry, Tyra Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyra Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Tyra Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tyra Biosciences's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-70.438	/	0
	=	%

Tyra Biosciences's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-19.596	/	0
	=	%

Tyra Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyra Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2656 State Street, Carlsbad, CA, USA, 92008

Website

https://www.tyra.bio

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Executives

Nina S Kjellson	director	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alan Fuhrman	officer: Chief Financial Officer	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Todd Harris	director, officer: Chief Executive Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Daniel Bensen	officer: Chief Operating Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ali D. Fawaz	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alta Partners Nextgen Fund Ii, L.p.	10 percent owner	4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert J More	director, 10 percent owner	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Melissa Mccracken	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008